Life sciences founders face a longer, more capital-intensive path to market than almost any other startup category, and the investors who back them need deep scientific fluency alongside patient capital. As 2025 approaches, a core group of US venture firms continues to anchor the therapeutics, diagnostics, and biotech-tools ecosystem. Below is a look at ten firms that remain active, well-capitalized, and central to how life sciences companies get funded.
OrbiMed
OrbiMed was founded in 1998 by Samuel Isaly after a split from his predecessor firm, Mehta & Isaly [2]. Based in New York City, the firm manages over $21 billion in assets, making it one of the largest dedicated healthcare investment organizations globally [1, 4]. OrbiMed employs a flexible mandate, investing from seed-stage venture capital through large public equities and private credit/royalty financings [1]. This multi-strategy approach allows it to provide non-dilutive capital to companies as they reach commercial milestones [1, 2]. Notable portfolio investments include AbCellera, a leader in antibody discovery platforms, and Argenx, a global immunology company where OrbiMed supported development from early stages [2, 5].
Versant Ventures
Versant Ventures was founded in 1999 by partners who spun out from several leading VC firms to build a healthcare-specialized practice [2]. Headquartered in San Francisco, the firm manages approximately $5.5 billion and operates with a highly distinctive "company creation" model [1, 2, 3]. Versant’s in-house "Discovery Engines" employ multi-disciplinary teams of scientists who re-run key experiments and validate academic IP independently before launching a startup [3, 4]. This model allows the firm to de-risk investments significantly at inception [4]. Notable portfolio companies include CRISPR Therapeutics, which the firm helped build, and Audentes Therapeutics, which was acquired for $3 billion [4].
Flagship Pioneering
Flagship Pioneering was founded in 2000 by Noubar Afeyan [2, 3]. Based in Cambridge, Massachusetts, Flagship is widely regarded as the pioneer of the "bioplatform" venture model, in which companies are conceived and built entirely in-house inside its lab environment [1, 2]. The firm is famous for founding Moderna, which validated its high-conviction, platform-first approach to medicine [2, 5]. Flagship’s ecosystem includes over 120 companies, focusing on solving "unreasonable" problems in health and sustainability [1]. Other notable companies created by the firm include Generate Biomedicines, which uses machine learning for protein design, and Indigo Agriculture, showing its breadth beyond standard therapeutics [2, 5].
Third Rock Ventures
Third Rock Ventures was founded in 2007 by former executives of Millennium Pharmaceuticals, including Mark Levin [1, 4]. With headquarters in Boston and San Francisco, Third Rock manages over $3.8 billion in committed capital [2]. Its model focuses on creating companies from the ground up, pairing disruptive scientific discoveries with a ready-made team of experienced operating executives [1]. This approach is designed to produce sustainable, high-impact companies rather than just funding projects [1]. A standout example is Editas Medicine, which Third Rock founded to pioneer CRISPR gene-editing therapies [2]. Another is Sage Therapeutics, where the firm’s operational model helped shepherd early clinical development in central nervous system disorders [2].
ARCH Venture Partners
ARCH Venture Partners traces its origins to a 1986 technology transfer initiative at the University of Chicago and Argonne National Laboratory, spinning out as an independent firm in 1992 [1, 2]. Headquartered in Chicago, the firm is known for making massive, early-stage bets on fundamental scientific breakthroughs [2, 4]. Managing roughly $12 billion, ARCH is famous for its long-horizon, high-conviction approach, often investing hundreds of millions into companies it creates [2, 4]. A historic win for the firm was Illumina, where it provided early support for what became the leader in genomics sequencing [2]. More recently, the firm has been instrumental in founding and scaling companies like Vir Biotechnology and Denali Therapeutics [2].
Polaris Partners
Polaris Partners was founded in 1996 in Boston by Jon Flint, Terry McGuire, and Steve Arnold [1]. The firm manages approximately $5 billion and invests across early and growth stages in healthcare and technology [1]. Polaris is highly regarded for its deep scientific diligence and long-term commitment to its entrepreneurs, frequently operating with an "innovation fund" that focuses specifically on commercializing academic research [1, 2]. Notable portfolio successes include a wide array of therapeutics and medtech developers. The firm’s collaborative culture, as cited by scientific founders like Dr. Bob Langer, has made it a preferred partner for both first-time and repeat biotechnology entrepreneurs [2].
5AM Ventures
5AM Ventures was founded in 2002 and is based in San Francisco, with a strong presence in Boston [1, 5]. Managing over $2.2 billion, the firm is a seed- and early-stage specialist focusing on biopharmaceutical drug development and life science tools [1, 5]. 5AM acts as a hands-on lead investor, often helping to structure and shape the company from its earliest inception [5]. The firm has guided more than 30 portfolio companies to IPO and over 20 to M&A exits [5]. Notable investments include Achaogen, which focused on multidrug-resistant bacterial infections, and Akouos, a gene therapy company later acquired by Eli Lilly [2].
RA Capital Management
RA Capital Management was founded in 2002 by Peter Kolchinsky and Richard Aldrich [2]. Headquartered in Boston, the firm manages over $14 billion and employs a unique "full-lifecycle" investment approach, investing in companies from seed through crossover financing and into the public markets [1, 5]. This continuity of capital is a major differentiator for the firm’s portfolio companies [1]. RA Capital’s research arm, TechAtlas, maintains detailed scientific "maps" of different therapeutic landscapes, which drive its data-heavy, evidence-based investment decisions [2, 4]. The firm’s portfolio includes argenx, which it supported through multiple stages of development, helping it grow into a global leader in immunology [4].
Sofinnova Investments
Sofinnova Investments was established in the U.S. in 1976 and is headquartered in Menlo Park, California [1, 2]. Managing over $4 billion, the firm invests across early-to-late stage biopharmaceutical and medtech companies [1, 2]. While it shares a name with the European firm Sofinnova Partners, the two are independent management entities [2]. Sofinnova Investments is known for its rigorous scientific diligence and its focus on helping companies navigate the regulatory and clinical paths to approval [1, 5]. Notable successful exits include a portfolio of companies that have collectively achieved 36 FDA drug approvals, reflecting the firm’s deep focus on clinical-stage execution [5].
MPM Capital
MPM Capital was founded in 1992 and is based in Boston [1, 5]. Managing over $3 billion, the firm is one of the most experienced biotech venture firms, operating now through its MPM BioImpact platform to support both private and public-impact investing [1, 5]. MPM is well-known for an "Entrepreneur Partner" model that brings seasoned biotech executives into the firm to build companies alongside its investment partners [4]. Its track record includes the early-stage founding of Moderna and Argenx, two of the most significant biotech companies of the last two decades [4, 5]. More recent efforts include the formation of Aktis Oncology, which is pioneering a new class of targeted alpha radiopharmaceuticals [1, 4].
What founders should take away
Picking the right life sciences investor is rarely just about check size. The best partners bring regulatory pattern-recognition, clinical trial design input, and credibility with downstream pharma partners. Several of the firms above, including Versant, Third Rock, Flagship, and ARCH, explicitly run company-creation models, meaning they may originate a competing concept internally rather than simply writing a check to an outside team; founders should understand a prospective investor's model before sharing proprietary data in a pitch. Before approaching any of the firms above, founders should have a clear view of their cap table and be ready to defend their valuation assumptions, something we unpack in our guide to valuation models for biotechnology startups. It's also worth revisiting the essentials of term sheets so you know which terms are standard in life sciences deals and which are negotiable, particularly around board composition and protective provisions, which tend to be more extensive in therapeutics deals given the long, milestone-driven path to an exit.
Founders should also expect life sciences diligence to run longer and deeper than in most software categories. Investors at these firms frequently bring in outside scientific advisors to evaluate a company's underlying biology or chemistry, and they will often want to see primary data rather than summarized results before committing to a term sheet. Building relationships with target investors well before a formal raise, through informal updates on research progress, can meaningfully shorten the diligence timeline once a round is actually launched.
Closing thoughts
The life sciences venture landscape remains concentrated among firms with deep scientific benches, and founders raising in this sector should prioritize fit over brand name. If you are preparing a Series A raise in therapeutics, diagnostics, or life sciences tools and want an outside perspective on your data room and investor targeting, book a free consult with Quantum Growth Advisors.